112900-82-0

Usage

Uses

Used in Chemical Synthesis Industry:
3-Methyl-4-(4-morpholinyl)aniline is used as an intermediate in the production of various chemical products, including dyes, pigments, and pharmaceuticals. Its unique structure allows it to serve as a building block for the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
3-Methyl-4-(4-morpholinyl)aniline is used as a precursor in the synthesis of pharmaceutical compounds. Its presence in the molecular structure can influence the properties and efficacy of the final drug product, making it a valuable component in the development of new medications.
Used in Dye and Pigment Industry:
3-Methyl-4-(4-morpholinyl)aniline is utilized as an intermediate in the production of dyes and pigments. Its chemical properties enable it to contribute to the color and stability of these products, which are used in a wide range of applications, including textiles, plastics, and printing inks.

Upstream product

• 455-88-9 5-nitro-2-fluorotoluene 
• 223404-63-5 3-methyl-4-(morpholin-4-yl)nitrobenzene 

Downstream Products

• 1026622-97-8 (R)-5-Hydroxymethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one 
• 1027534-10-6 (S)-5-Aminomethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one 
• 1026410-10-5 (R)-5-Azidomethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one 
• 1027386-00-0 (R)-5-Isothiocyanatomethyl-3-(3-methyl-4-morpholin-4-yl-phenyl)-oxazolidin-2-one 
• 1027184-22-0 Methanesulfonic acid (R)-3-(3-methyl-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester 
• 1431522-31-4 C₃₁H₂₈ClN₅O₂ 
• 1431522-32-5 C₃₁H₂₈FN₅O₂ 
• 892491-51-9 C₁₃H₁₈N₄O₃ 
• 892491-35-9 C₁₄H₁₈N₂O₄ 

Relevant academic research and scientific papers

Quinoline derivative, and preparation method and uses thereof

The invention relates to a quinoline derivative, and a composition including the derivative, and also relates to a preparation method of the derivative, and uses of the derivative in the prevention ortreatment of harmful fungi and the killing of pests.

Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)

Stem cell factor receptor (c-KIT) and platelet derived growth factor receptor alpha (PDGFRα) kinases play an important role in gastrointestinal stromal tumors (GISTs). Here, we have discovered an c-KIT/PDGFRα dual inhibitor, compound 31, with single-digit nanomolar potency against c-KIT and PDGFRα. Compared to Imatinib (1), 31 showed better antiproliferative efficacy against various TEL-c-KIT/PDGFRα-BaF3 isogenic cells, including three 1-resistant BaF3 cell lines, as well as against GIST-T1 and GIST-882 cell lines. Furthermore, compound 31 showed a good KinomeScan selectivity (468 kinases) (S score (1) = 0.01 at 1 μM concentration), good metabolic stability in liver microsomes, and no hERG inhibitory activity. It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.

COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS

The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

VEGFR TYROSINE KINASE INHIBITORS

Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS

Compounds of formula (Ia) are found to be active in inhibiting replication of flaviviridae viruses, wherein R1, R2, R3 and R4 are as defined in the claims.

Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 2.1) Relationship between lipophilicity and antibacterial activity in 5-thiocarbonyl oxazolidinones

5-Thiourea and 5-dithiocarbamate oxazolidinones were synthesized as a continuation of research on 5-thiocarbonyl oxazolidinone antibacterial agents considering the hydrophobic parameters of the molecule. The structure-activity relationship (SAR) study revealed that the antibacterial activity on 5-thiocarbonyl oxazolidinones was significantly affected by the lipophilicity, especially the calculated log P value and the balance between 5-hydrophilic (or hydrophobic) substituent and hydrophobic (or hydrophilic) substituents on the benzene ring. Some of 5-thiocarbonyl oxazolidinones were found to have good in vitro antibacterial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).